Verastem reported its entry into an amendment to its Loan and Security Agreement with Hercules Capital, increasing its existing borrowing limit under the loan facility from $25 million to up to $50 million in financing. On January 4, the company noted that the increased loan facility proceeds will be available for the company ongoing development programs, including regulatory and commercialization activities for duvelisib, and for general corporate purposes. The company has received the first $15 million of financing under the original Loan and Security Agreement. Additional tranches of up to $35 million in aggregate will be available to the company to drawdown subject to certain conditions, including the U.S. Food and Drug Administration's (FDA) acceptance of the company's New Drug Application (NDA) for duvelisib. The additional funds available under the facility will only accrue interest and principal repayments upon drawdown by the company.